AVRX Avalon Pharmaceuticals (MM)

GERMANTOWN, Md., Nov. 1 /PRNewswire-FirstCall/ -- Avalon Pharmaceuticals, Inc. (NASDAQ:AVRX) and (NYSE Arca: AVRX) today announced that it is scheduled to release financial results for the third quarter and year to date of 2006, on Tuesday, November 7, 2006 after the close of the U.S. financial markets. The Company will host a conference call on Wednesday, November 8, 2006 at 8:00 a.m. Eastern Time to provide a company update and discuss the financial results for the quarter. Interested investors, analysts, members of the media and the general public can listen to the call live over the Internet from the investor section of the Company's website or by dialing the numbers listed below. Conference Call Details: ------------------------ Dial-In: 800.561.2813 (U.S.) 617.614.3529 (International) Passcode: 80900111 Webcast: Please go to http://www.avalonrx.com/, Investors, within 15 minutes prior to the call and select the webcast link. The conference call replay will be available through December 30, 2006 on Avalon's website (http://www.avalonrx.com/). About Avalon Pharmaceuticals Avalon Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics through the use of a comprehensive, innovative and proprietary suite of technologies based upon large-scale gene expression analysis which it calls AvalonRx(R). This platform facilitates drug discovery by expanding the range of therapeutic targets for drug intervention, including targets and target pathways frequently considered intractable using conventional HTS approaches, allows more informed decisions about which compounds to advance towards clinical trials, and facilitates drug development through identification of biomarkers of efficacy that can stratify patients or provide early indicators of response. Avalon's focus is oncology but has discovery programs in other therapeutic areas with partners. Avalon Pharmaceuticals was established in 1999 and is headquartered in Germantown, Maryland. DATASOURCE: Avalon Pharmaceuticals, Inc. CONTACT: Gary Lessing, Executive Vice President and CFO of Avalon Pharmaceuticals, +1-301-556-9900, or Fax: +1-301-556-9910, or Web site: http://www.avalonrx.com/

Copyright